Protein / target
Voltage-dependent calcium channel gamma-4 subunit
Protein at a glance
Biological role
Voltage-gated calcium channel activity
Primary system
Nervous system
Strongest disease association
epilepsy
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
7 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit (PubMed:21127204). Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs), including GRIA1 and GRIA4. Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization and by mediating their resensitization (PubMed:21172611)
Subcellular location
Domains and Gene Ontology detail (19)Hide
Gene Ontology
- CAMPA glutamate receptor complex
- Ccell body
- Ccell surface
- Cendocytic vesicle membrane
- Cglutamatergic synapse
- CL-type voltage-gated calcium channel complex
- Cplasma membrane
- Cpostsynaptic density membrane
- Csomatodendritic compartment
- Fcalcium channel regulator activity
- Fchannel regulator activity
- Fionotropic glutamate receptor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming s…
- ·glutamatergic synapse
- ·postsynaptic density membrane
- ·positive regulation of synaptic transmission, glutamatergic
Excitatory neurotransmission
- ·glutamatergic synapse
- ·positive regulation of synaptic transmission, glutamatergic
View underlying pathways (5)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Voltage-gated calcium channel modulator
Appears in clinical studies involving Seizure, epilepsy, Focal-onset seizure, restless legs syndrome
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 157 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 10 total
cardiovascular disorder
restless legs syndrome · neuralgia · Sleep disturbance
insomnia
cardiovascular disorder
Seizure · epilepsy · Focal-onset seizure
Polyuria · Urinary incontinence
gastrointestinal disease · urinary system disorder · renal colic
Seizure · neuropathic pain · fibromyalgia
generalized anxiety disorder
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: GABAPENTIN (ANDA217995)
- Label change
Label change: GABAPENTIN (ANDA203934)
- Label change
Label change: GABAPENTIN (ANDA075428)
- Label change
Label change: GABAPENTIN (ANDA077661)
- Regulatory approval
Approval: GABAPENTIN (ANDA203611)
- Label change
Label change: GABAPENTIN (ANDA217995)
- Label change
Label change: GABAPENTIN (ANDA075428)
- Label change
Label change: GABAPENTIN (ANDA075428)
- Label change
Label change: GABAPENTIN (ANDA075428)
- Regulatory approval
Approval: GABAPENTIN (ANDA203934)
- Label change
Label change: GABAPENTIN (ANDA077661)
- Label change
Label change: GABAPENTIN (ANDA077661)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.